RxDoctor Payments Data

George Keith, MD

Internal Medicine · Houston, TXNPI 1598748873

Payments from drug & device makers

$22,638in general payments, 2019–2025

Across 1,151 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$3K
  • Boehringer Ingelheim$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Grifols USA, LLC$1K
  • Philips North America LLC$1K
  • plus $10K from 46 others

What the payments were for

  • Food & beverage$22,50599%
  • Education$1331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,638 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$231,186
Medicare patients
681
Services billed
2,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate74$962,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter167$170,546
EliquisApixaban111$101,196
OzempicSemaglutide72$83,654
FasenraBenralizumab12$65,975
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$44,814
Breo ElliptaFluticasone/Vilanterol68$44,387
JanuviaSitagliptin Phosphate23$25,017
XareltoRivaroxaban23$24,927
Pirfenidone12$24,000
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$19,328
TrulicityDulaglutide11$18,792
MyrbetriqMirabegron20$16,714
Bevespi AerosphereGlycopyrrolate/Formoterol Fum24$15,994
Albuterol Sulfate HfaAlbuterol Sulfate403$14,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$1,811$977,039100 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$3,340$234,261274 claims
AstraZenecaFasenra, Breztri Aerosphere, Bevespi Aerosphere, Symbicort$3,506$134,870107 claims
Novo NordiskOzempic$21$83,65472 claims
MerckJanuvia, Dulera$125$35,07348 claims
Johnson & JohnsonXarelto$197$24,92723 claims
Lilly USA, LLCTrulicity$20$18,79211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →